Clinical trials: Advanced Malignant Tumor
Solid Tumor, Pancreatic Cancer
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.
- Trial name
- NCT06245330
- Testing
- AST-001
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Ascentawits Pharmaceuticals, Ltd
Small Cell Lung Cancer, Neuroendocrine Carcinoma
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789.
- Trial name
- NCT05619744
- Testing
- RO7616789, Tocilizumab
- Where
- 17 sites in United States, Denmark and 3 more
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Lymphoma
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when…
- Trial name
- NCT03249792
- Testing
- MK-2118 (IT), MK-2118 (SC), Pembrolizumab
- Where
- 8 sites in United States, Israel
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Solid Tumor
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.
- Trial name
- NCT06368921
- Testing
- VRT106
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
Locally-Advanced Non-Small Cell Lung Cancer, Radiotherapy
Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC
This is a single-center, prospective, open-label, single-arm phase I exploratory study designed to evaluate the safety and feasibility of a novel central immune-priming radiotherapy strategy in patients with unresectable stage…
- Trial name
- NCT07523464
- Testing
- Centrally Confined 8 Gy/1 Fraction Immune-Priming Radiotherapy to the Tumor Core Followed by Definitive Concurrent Chemoradiotherapy
- Volunteers
- 24 people
- Sponsor
- Anhui Provincial Hospital
Advanced Malignant Solid Tumor
A Study of MHB009C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB009C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07326488
- Testing
- MHB009C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Malignant Pleural Mesothelioma
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced…
- Trial name
- NCT04713761
- Testing
- Toripalimab
- Volunteers
- 15 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial
This phase II trial compares the effect of combination therapy with capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body…
- Trial name
- NCT05247905
- Testing
- Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide
- Where
- 171 sites in United States
- Volunteers
- 31 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Melanoma, Skin Cancer
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Background: Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. An experimental procedure developed for treating patients with melanoma uses the anti-MART-1 F5 gene and a type of virus to make…
- Trial name
- NCT00612222
- Testing
- autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well giving imatinib mesylate together with paclitaxel works in treating older patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00408460
- Testing
- imatinib mesylate, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Cervical Cancer
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
This is a phase II, prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with iparomlimab and tuvonralimab as neoadjuvant therapy in patients with…
- Trial name
- NCT07348861
- Testing
- Sacituzumab tirumotecan plus Iparomlimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zheng Min
Gastrointestinal Stromal Tumor
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
A Phase II Study of AUY922, Novel HSP Inhibitor, in Patients with Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy Primary endpoint: •The primary endpoint of this study is to assess disease control rate…
- Trial name
- NCT01389583
- Testing
- AUY922
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- National Health Research Institutes, Taiwan
Advanced Cancer, Advanced Solid Tumor
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT06540066
- Testing
- BGB-B3227, Tislelizumab, Chemotherapy
- Where
- 12 sites in United States, China and 1 more
- Volunteers
- 35 people
- Sponsor
- BeiGene
Solid Tumor
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
This is the first-in-human study with SYD1875, an antibody-drug conjugate (ADC) comprising of a humanized IgG1 monoclonal antibody directed against the 5T4 oncofetal antigen covalently conjugated to a duocarmycin-based…
- Trial name
- NCT04202705
- Testing
- SYD1875
- Where
- 3 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Byondis B.V.
Tumors
Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan
The study will evaluate the safety and efficacy of Patupilone in adult patients with advanced solid tumors.
- Trial name
- NCT00412789
- Testing
- Patupilone
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Rectal Cancer
Response Assessment by Circulating Tumor DNA in Patients With Locally Advanced Rectal Cancer
This is a single-arm observational study to determine the feasibility of assessing tumor response utilizing Circulating tumor DNA (ctDNA) in patients of with locally advanced rectal cancer (LARC) undergoing standard-of-care total…
- Trial name
- NCT04670588
- Testing
- Circulating tumor DNA(ctDNA) level measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Advanced Melanoma
Phase II FANG™ in Advanced Melanoma
Preliminary studies with a variety of vaccines suggest target accessibility (potential immunogenicity) in a variety of solid tumors to immune directed approaches.
- Trial name
- NCT01453361
- Testing
- Vigil™ Vaccine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gradalis, Inc.
Malignant Mesothelioma
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated…
- Trial name
- NCT00509041
- Testing
- dasatinib
- Where
- 37 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Malignant Tumors
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of DS-6051b in Japanese subjects with advanced solid malignant tumors harboring either a ROS1 or NTRK fusion gene.
- Trial name
- NCT02675491
- Testing
- DS-6051b
- Where
- 3 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.